1. Home
  2. CTKB vs AVXL Comparison

CTKB vs AVXL Comparison

Compare CTKB & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytek Biosciences Inc.

CTKB

Cytek Biosciences Inc.

HOLD

Current Price

$4.85

Market Cap

433.8M

Sector

Health Care

ML Signal

HOLD

Logo Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp.

HOLD

Current Price

$4.01

Market Cap

397.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTKB
AVXL
Founded
1990
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
433.8M
397.6M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
CTKB
AVXL
Price
$4.85
$4.01
Analyst Decision
Hold
Strong Buy
Analyst Count
4
3
Target Price
$5.88
$22.00
AVG Volume (30 Days)
1.9M
4.1M
Earning Date
11-05-2025
11-25-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$196,828,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.62
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.37
$2.86
52 Week High
$7.30
$14.44

Technical Indicators

Market Signals
Indicator
CTKB
AVXL
Relative Strength Index (RSI) 47.20 36.99
Support Level $4.79 $3.96
Resistance Level $5.16 $4.88
Average True Range (ATR) 0.24 0.41
MACD -0.11 0.20
Stochastic Oscillator 9.57 55.44

Price Performance

Historical Comparison
CTKB
AVXL

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Share on Social Networks: